Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts
Purpose: Prostate cancer is multifocal. However, there often exists a single dominant focus in the gland responsible for driving the biology of the disease. Dose escalation to the dominant lesion is a proposed strategy to increase tumor control. We applied radiobiological modeling to evaluate the do...
Main Authors: | Christopher D. Goodman, MD, Hatim Fakir, PhD, Stephen Pautler, MD, Joseph Chin, MD, Glenn S. Bauman, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-03-01
|
Series: | Advances in Radiation Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452109419301484 |
Similar Items
-
Dosimetric Uncertainties in Dominant Intraprostatic Lesion Simultaneous Boost Using Intensity Modulated Proton Therapy
by: Jun Zhou, PhD, et al.
Published: (2022-01-01) -
Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour
by: Mathieu Gaudreault, et al.
Published: (2022-07-01) -
Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga- PSMA PET/CT
by: Khadijeh Bamneshin, et al.
Published: (2022-08-01) -
Can Polymetastatic Disease Be ARRESTed Using SABR? A Dosimetric Feasibility Study to Inform Development of a Phase 1 Trial
by: Mark T. Corkum, MD, MSc, et al.
Published: (2021-09-01) -
Comparison of Manual and Semi-Automatic [18F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference
by: Simon K. B. Spohn, et al.
Published: (2020-12-01)